Tim-3 on neutrophils in ankylosing spondylitis
Part of Bones, joints & muscles clinical trials.
This study looks at a protein called Tim-3 on certain white blood cells (neutrophils) in people with ankylosing spondylitis, to understand inflammation better. It may help find new ways to treat the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of ankylosing spondylitis (by standard criteria).
- You cannot have other autoimmune diseases (like lupus or rheumatoid arthritis).
- You cannot have an active infection that affects inflammation markers.
- You cannot have certain health issues: uncontrolled high blood pressure, kidney failure, chronic liver disease, cancer, diabetes, a pacemaker, or be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This study looks at whether a substance called interleukin-33 (a protein involved in inflammation) is higher in people with ankylosing spondylitis and whether it is related to early signs of hardening of the arteries. It aims to better understand the connection between spinal inflammation and heart health.
This research study measures a specific blood protein (IL-41) in people with two types of inflammatory arthritis: ankylosing spondylitis (which affects the spine) and psoriatic arthritis (which affects joints and skin). Understanding this marker may help doctors better diagnose and monitor these conditions.
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.
This trial is for people with ankylosing spondylitis (a type of arthritis that affects the spine) who are otherwise healthy. It may test a treatment to see if it helps control symptoms, whether your disease is active or stable.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.